Workflow
Biodesix(BDSX)
icon
Search documents
Biodesix(BDSX) - 2023 Q1 - Earnings Call Transcript
2023-05-14 15:53
Biodesix, Inc. (NASDAQ:BDSX) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Alex Vukasin - Canaccord Genuity Operator Good day, and thank you for standing by and welcome to the Biodesix First Quarter 2023 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers presentation there will be ...
Biodesix(BDSX) - 2023 Q1 - Quarterly Report
2023-05-10 16:00
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR Delaware 20-3986492 (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 2970 Wilderness Place, Suite 100 Boulder, Colorado 80301 80301 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (303) 417-0500 Non-accelerated filer If an emerging growth company, indicate ...
Biodesix(BDSX) - 2022 Q4 - Earnings Call Transcript
2023-03-06 15:09
Biodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Conference Call March 6, 2023 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Andrew Brackmann - William Blair Operator Good day, and thank you for standing by. Welcome to the Biodesix Fourth Quarter and Year-End 2022 Earnings Conference Call. At this time all participants are in a listen-only mode. After the ...
Biodesix(BDSX) - 2022 Q4 - Annual Report
2023-03-05 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39659 Biodesix, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-3986492 (State or other jurisdiction of (I.R. ...
Biodesix(BDSX) - 2022 Q3 - Earnings Call Transcript
2022-11-06 14:53
Biodesix, Inc. (NASDAQ:BDSX) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET Company Representatives Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Chris Brinzey - Investor Relations Conference Call Participants Andrew Brackmann - William Blair Max Masucci - Cowen & Company Kyle Mikson - Canaccord Genuine Operator Good day! And thank you for standing by. Welcome to the Biodesix, Third Quarter 2022 Earnings Conference Call. At this time all participants are i ...
Biodesix(BDSX) - 2022 Q3 - Quarterly Report
2022-11-03 10:13
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 | --- | --- | --- | |-------------------------------------------------------------------------------------------------- ...
Biodesix(BDSX) - 2022 Q2 - Earnings Call Transcript
2022-08-06 17:28
Biodesix, Inc. (NASDAQ:BDSX) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Max Masucci - Cowen Kyle Mikson - Canaccord Operator Good morning. My name is Joanne and I will be your conference operator today. At this time, I would like to welcome everyone to the Biodesix Second Quarter 2022 Earnings ...
Biodesix(BDSX) - 2022 Q2 - Quarterly Report
2022-08-04 10:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 | --- | --- | --- | |------------------------------------------------------------------------------------------------------- ...
Biodesix(BDSX) - 2022 Q1 - Earnings Call Transcript
2022-05-11 15:48
Biodesix, Inc. (NASDAQ:BDSX) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Chris Brinzey - IR Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Brian Weinstein - William Blair & Company Kyle Mikson - Canaccord Genuity Max Masucci - Cowen and Company Operator Hello. Thank you for standing by, and welcome to Biodesix First Quarter 2022 Earnings Conference Call. [Operator Instructions]. I would now like to hand the con ...
Biodesix(BDSX) - 2022 Q1 - Quarterly Report
2022-05-11 10:16
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39659 BIODESIX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 20-3986492 (State or other jurisdiction of i ...